Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum

Yuxiong Gao; Zhendong Chen; Changyong Yang; Dafang Zhong

doi:10.1016/j.jpha.2020.08.005

Volume 11 Issue 4

Aug. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2021 > 11(4): 472-479

Yuxiong Gao, Zhendong Chen, Changyong Yang, Dafang Zhong. Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum[J]. Journal of Pharmaceutical Analysis, 2021, 11(4): 472-479. doi: 10.1016/j.jpha.2020.08.005

Citation:

Yuxiong Gao, Zhendong Chen, Changyong Yang, Dafang Zhong. Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum[J]. Journal of Pharmaceutical Analysis, 2021, 11(4): 472-479. doi: 10.1016/j.jpha.2020.08.005

Citation:

Yuxiong Gao, Zhendong Chen, Changyong Yang, Dafang Zhong. Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum[J]. Journal of Pharmaceutical Analysis, 2021, 11(4): 472-479. doi: 10.1016/j.jpha.2020.08.005

PDF( 1311 KB)

Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum

doi: 10.1016/j.jpha.2020.08.005

a. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China;
b. University of Chinese Academy of Sciences, Beijing, 100049, China;
c. Preclinical Department, Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, 222047, China

Funds:

This study was supported by the National Natural Science Foundation of China (Grant No. 81521005) and the National Key Research Project of the Chinese Academy of Sciences (Grant No. XDA12050306).

Received Date: Feb. 28, 2020
Accepted Date: Aug. 09, 2020
Rev Recd Date: Jul. 01, 2020
Available Online: Jan. 24, 2022
Publish Date: Aug. 15, 2021

Abstract

Abstract

Liquid chromatography tandem mass spectrometry (LC-MS/MS) has gradually become a promising alternative to ligand binding assay for the bioanalysis of biotherapeutic molecules, due to its rapid method development and high accuracy. In this study, we established a new LC-MS/MS method for the determination of the anti-sclerostin monoclonal antibody (SHR-1222) in cynomolgus monkey serum, and compared it to a previous electrochemiluminescence method. The antibody was quantified by detecting the surrogate peptide obtained by trypsin digestion. The surrogate peptide was carefully selected by investigating its uniqueness, stability and MS response. The quantitative range of the proposed method was 2.00–500 μg/mL, and this verified method was successfully applied to the toxicokinetic assessment of SHR-1222 in cynomolgus monkey serum. It was found that the concentrations of SHR-1222 in cynomolgus monkeys displayed an excellent agreement between the LC-MS/MS and electrochemiluminescence methods (ratios of drug exposure, 0.8–1.0). Notably, two monkeys in the 60 mg/kg dose group had abnormal profiles with a low detection value of SHR-1222 in their individual sample. Combining the high-level anti-drug antibodies (ADAs) in these samples and the consistent quantitative results of the two methods, we found that the decreased concentration of SHR-1222 was due to the accelerated clearance mediated by ADAs rather than the interference of ADAs to the detection platform. Taken together, we successfully developed an accurate, efficient and cost-effective LC-MS/MS method for the quantification of SHR-1222 in serum samples, which could serve as a powerful tool to improve the preclinical development of antibody drugs.
- Anti-sclerostin monoclonal antibody,
- (SHR-1222),
- LC-MS/MS,
- Anti-drug antibody,
- Toxicokinetic

FullText(HTML)

References(31)

References

H. Kaplon, M. Muralidharan, Z. Schneider, et al., Antibodies to watch in 2020, Mabs. 12 (2020) 1703531. https://doi.org/10.1080/19420862.2019.1703531

C.W. Lindsley, New 2016 Data and statistics for global pharmaceutical products and projections through 2017. ACS Chem. Neurosci. 8 (2017) 1635-1636. https://doi.org/10.1021/acschemneuro.7b00253

Y. Rosenberg-Hasson, L. Hansmann, M. Liedtke, et al., Effects of serum and plasma matrices on multiplex immunoassays. Immunol. Res. 58 (2014) 224-233. https://doi.org/10.1007/s12026-014-8491-6

W. Wang, E.Q. Wang, J.P. Balthasar, Monoclonal antibody pharmacokinetics and pharmacodynamics, Clin. Pharmacol. Ther. 84 (2008) 548-558. https://doi.org/10.1038/clpt.2008.170

O.H. Brekke, I. Sandlie, Therapeutic antibodies for human diseases at the dawn of the twenty-first century, Nat. Rev. Drug Discov. 2 (2003) 52-62. https://doi.org/10.1038/nrd1060

M. Kelley, B. DeSilva, Key elements of bioanalytical method validation for macromolecules, AAPS J. 9 (2007) E156-E163. https://doi.org/10.1208/aapsj0902017

A.S. Rosenberg, A. Worobec, A risk-based approach to immunogenicity concerns of therapeutic protein products Part 1 Considering consequences of the immune response to a protein, Biopharm. Int. 17 (2004) 22

G. Shankar, C. Pendley, K.E. Stein, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nat. Biotechnol. 25 (2007) 555-561. https://doi.org/10.1038/nbt1303

G. Shankar, D. Finko-Kent, B. Rup, et al., Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products, J. Immunol. Methods. 333 (2008) 1-9. https://doi.org/10.1016/j.jim.2008.01.001

C.W.N. Damen, J.H.M. Schellens, J.H. Beijnen, Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies, Hum. Antibodies. 18 (2009) 47-73. https://doi.org/10.3233/HAB-2009-0206

J.W. Lee, M. Kelley, L. E. King, et al., Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development, AAPS J. 13 (2011) 99-110. https://doi.org/10.1208/s12248-011-9251-3

B.A.P. Buscher, H. Gerritsen, I.V. Scholl, et al., Quantitative analysis of Tenecteplase in rat plasma samples using LC-MS/MS as an alternative for ELISA, J. Chromatogr. B. 852 (2007) 631-634. https://doi.org/10.1016/j.jchromb.2006.12.053

S.T. Wu, Z. Ouyang, T.V. Olah, et al., A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water-miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection Rapid Commun. Mass SP. 25 (2011) 281-290. https://doi.org/10.1002/rcm.4856

H.C. Liu, A.V. Manuilov, C. Chumsae, et al., Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry, Anal. Chem. 414 (2011) 147-153. https://doi.org/10.1016/j.ab.2011.03.004

H. Jiang, J Zeng, C. Titsch C, et al., Fully validated LC-MS/MS assay for the simultaneous quantitation of co-administered therapeutic antibodies in cynomolgus monkey serum, Anal. Chem. 85(2013), 9859-9867. https://doi.org/10.1021/ac402420v

Y.X. Gao, D. Zhang, C.Y. Yang, et al., Two validated liquid chromatography-mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method, J. Pharm. Biome. Anal. 175 (2019) 112792. https://doi.org/10.1016/j.jpba.2019.112792

A.S. Rosenberg, A. Worobec, A risk-based approach to immunogenicity concerns of therapeutic protein products. Part II: Considering host-specific and product-specific factors impacting immunogenicity, Biopharm Int. 17 (2004) 34-42

G. Shankar, C. Pendley, K.E. Stein. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nat. Biotechnol. 25 (2007) 555-561. https://doi.org/10.1038/nbt1303

A. Johansson, A. Erlandsson, D. Eriksson, et al., Idiotypic-anti-idiotypic complexes and their in vivo metabolism, Cancer 94 (2002) 1306-1313

J.M. Sailstad, L. Amaravadi, Clements-Egan A, et al., A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements, AAPS J. 16 (2014) 488-498. https://doi.org/10.1208/s12248-014-9582-y

T.M. Thway, L. Magana, A. Bautista, et al., Impact of anti-drug antibodies in preclinical pharmacokinetic assessment, AAPS J. 15 (2013) 856-863. https://doi.org/10.1208/s12248-013-9484-4

J.S. Wang, S.T. Wu, J. Gokemeijer, et al., Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies, Anal. Bioanal. Chem. 402 (2012) 1229-1239. https://doi.org/10.1007/s00216-011-5527-9

J.R. Rojas, R.P. Taylor, M.R. Cunningham, et al., Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys, J. Pharm. Exp. Ther. 313 (2005) 578-585. https://doi.org/10.1124/jpet.104.079277

R. Jenkins, J.X. Duggan, A.F. Aubry, et al., Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics, AAPS J. 17 (2015) 1-16

C. Paszty, C.H. Turner, M.K. Robinson, Sclerostin: A gem from the genome leads to bone-building antibodies, J. Bone Miner. Res. 25 (2010) 1897-1904. https://doi.org/10.1002/jbmr.161

Z.D. Zhong, S. Dinnogen, M. Hokom, et al., Identification and inhibition of drug target interference in immunogenicity assays, J. Immunol. Methods. 355 (2010) 21-28. https://doi.org/10.1016/j.jim.2010.02.008

E.M. Lewiecki. Monoclonal antibodies for the treatment of osteoporosis, Expert. Opin. Biol. Ther. 13 (2013) 183-196. https://doi.org/10.1517/14712598.2012.740006

F. Cosman, D.B. Crittenden, J.D. Adachi, et al., Romosozumab treatment in postmenopausal women with osteoporosis, New Engl. J. Med. (2016) NEJMoa1607948. https://doi.org/10.1056/NEJMoa1607948

D. Zhang, C.Y. Yang, X.Y. Chen, et al., A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222, Bioanalysis. (2018) bio-2017-0289-. https://doi.org/10.4155/bio-2017-0289

Chinese Pharmacopoeia Commission, General Chapter 0912, Chinese Pharmacopoeia. Beijing, China, 2015

European Medicines Agency (EMA), Guideline on Bioanalytical Method Validation, EMA, London, U.K., 2012

Relative Articles

Supplements(0)

Cited By

Proportional views